Use of Botulinum Toxin to Treat Psoriasis
Phase 1
Completed
- Conditions
- Psoriasis Vulgaris
- Interventions
- Biological: injection of botulinum toxin type A.
- Registration Number
- NCT00816517
- Lead Sponsor
- University of Minnesota
- Brief Summary
Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation.
Recently, it was reported that patients who suffered from dystonia and had concomitant psoriasis, when treated with botulinum toxin for dystonia noted a dramatic improvement of their psoriatic lesions.
This pilot study will determine the safety and efficacy of botulinum toxin in the management of psoriasis vulgaris.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- Healthy subjects. Psoriasis vulgaris diagnosis made by a board certified dermatologist involving at least one area that has been intolerant or recalcitrant to at least two forms of recognized topical or systemic treatments in the past. In addition, the subject should have at least a score of 2 for keratoderma and erythema. Signed informed consent. Willing to adhere to protocol.
Exclusion Criteria
- Immunosuppressed patients, pregnant, secondary skin infections, phototherapy within 4 weeks of the botulinum toxin injection, exposure to any topical or systemic retinoid treatment with the last 12 months, volunteers taking chloroquine and hydroxychloroquine, volunteers on warfarin.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description botulinum toxin injection of botulinum toxin type A. injection of botulinum toxin type A
- Primary Outcome Measures
Name Time Method psoriasis scoring scale baseline and 3months
- Secondary Outcome Measures
Name Time Method 3mm skin biopsy. baseline and at 3 months.
Trial Locations
- Locations (1)
Univerisity of Minnesota
🇺🇸Minneapolis, Minnesota, United States